Kinnate Biopharma Inc. Receives Consensus Recommendation of Hold from Analysts

KNTEDelisted Stock  USD 2.96  0.27  8.36%   
About 61% of Kinnate Biopharma's investor base is looking to short. The analysis of current outlook of investing in Kinnate Biopharma suggests that many traders are alarmed regarding Kinnate Biopharma's prospects. The current market sentiment, together with Kinnate Biopharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Kinnate Biopharma stock news signals to limit their universe of possible portfolio assets.
  
Shares of Kinnate Biopharma Inc. have received an average recommendation of Hold from the five brokerages that are currently covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average twelve-month target

Read at thelincolnianonline.com
news
  

Kinnate Biopharma Fundamental Analysis

We analyze Kinnate Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kinnate Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kinnate Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Short Ratio

Short Ratio Comparative Analysis

Kinnate Biopharma is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.

Kinnate Biopharma Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kinnate Biopharma stock to make a market-neutral strategy. Peer analysis of Kinnate Biopharma could also be used in its relative valuation, which is a method of valuing Kinnate Biopharma by comparing valuation metrics with similar companies.

Peers

Kinnate Biopharma Related Equities

IPSCCentury Therapeutics   20.74   
0%
100.0%
KRONKronos Bio   10.34   
0%
49.0%
SRZNSurrozen   8.96   
0%
43.0%
WINTWindtree Therapeutics   8.93   
0%
43.0%
CCCCC4 Therapeutics   8.59   
0%
41.0%
LRMRLarimar Therapeutics   7.44   
0%
35.0%
GLUEMonte Rosa   5.93   
0%
28.0%
ERASErasca   5.04   
0%
24.0%
BOLTBolt Biotherapeutics   5.00   
0%
24.0%
KROSKeros Therapeutics   2.02   
0%
9.0%
STOKStoke Therapeutics   1.19   
0%
5.0%
PALIPalisade Bio   0.83   
0%
4.0%
EWTXEdgewise Therapeutics   0.37   
0%
1.0%
KZRKezar Life   0.40   
1.0%
0%
GBIOGeneration Bio   0.69   
3.0%
0%
SLRNACELYRIN, INC   1.51   
7.0%
0%
DSGNDesign Therapeutics   2.93   
14.0%
0%
PASGPassage Bio   10.67   
51.0%
0%
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Other Consideration for investing in Kinnate Stock

If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Global Correlations
Find global opportunities by holding instruments from different markets